GlassScriptPhysician profile
Melissa B Blom
NPI 1518288406
$11,783.93
in general payments reported to CMS, 2019-2025
31 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,148 · 2022: $3,357 · 2023: $3,706 · 2024: $2,144 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,266 · Education: $13.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,266.10 |
| Education | $13.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,616.45 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Mallinckrodt Hospital Products INC. | $1,984.72 | 2021-2025 | Acthar |
| Ucb, INC. | $894.05 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $787.65 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $573.83 | 2021-2025 | |
| Abbvie INC. | $560.88 | 2021-2025 | Rinvoq |
| Lilly USA, LLC | $467.45 | 2021-2024 | Taltz |
| Glaxosmithkline, LLC. | $451.04 | 2021-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.91 | 2021-2024 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $338.52 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $256.06 | 2022-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $240.33 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $167.35 | 2021-2023 | Tymlos |
| Novartis Pharmaceuticals Corporation | $142.14 | 2023 | |
| Ani Pharmaceuticals, INC. | $108.42 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $88.33 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $87.56 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $84.50 | 2024-2025 | Orencia |
| United Therapeutics Corporation | $72.46 | 2021 | |
| Sobi, INC | $56.08 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $53.98 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $48.48 | 2022-2023 | |
| Almatica Pharma LLC | $47.72 | 2024 | Teriparatide |
| Kyowa Kirin, INC. | $42.28 | 2023-2024 | Crysvita |
| Sandoz INC. | $37.91 | 2023-2024 | Hyrimoz |
| Kiniksa Pharmaceuticals, LTD. | $37.37 | 2023 | Arcalyst |
| Fresenius Kabi USA, LLC | $25.95 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $17.91 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.35 | 2021 | |
| Fidia Pharma USA INC. | $15.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Blom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.